Scarica l'app Stockscreener
7.83
2.86%
-0.21
Precedente Chiudi:
$8.04
Aprire:
$7.89
Volume 24 ore:
182.60K
Relative Volume:
0.24
Capitalizzazione di mercato:
$584.94M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-13.98
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
-0.64%
1M Prestazione:
+8.62%
6M Prestazione:
+115.75%
1 anno Prestazione:
-14.18%
Intervallo 1D:
$7.622
$7.94
Intervallo di 1 settimana:
$7.46
$8.44
Portata 52W:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Confronta CRVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
7.85 | 599.09M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.60 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.88 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.71 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.01 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Corvus to present final data on T cell lymphoma drug at ASH meeting - Investing.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikesTrade Signal Summary & High Win Rate Trade Tips - newser.com
Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan
How to build a dashboard for Corvus Pharmaceuticals Inc. stockDip Buying & Stepwise Trade Signal Implementation - newser.com
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Why Corvus Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming base2025 Big Picture & Verified Entry Point Signals - newser.com
What momentum indicators show for Corvus Pharmaceuticals Inc. stockJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Real time social sentiment graph for Corvus Pharmaceuticals Inc.Quarterly Trade Report & High Win Rate Trade Tips - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.Quarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm
Corvus Pharmaceuticals Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Corvus Pharmaceuticals, Inc. (CRVS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Corvus Pharmaceuticals, Inc. (CRVS) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Corvus Pharmaceuticals Inc. recovery potential after sell offEarnings Performance Report & Verified Short-Term Plans - newser.com
Corvus Pharmaceuticals Inc. stock momentum explained2025 Analyst Calls & Precise Buy Zone Tips - newser.com
ETFs Investing in Corvus Pharmaceuticals, Inc. Stocks - TradingView
Will Corvus Pharmaceuticals Inc. stock benefit from green energy trendsEarnings Risk Report & Growth Focused Entry Reports - Fundação Cultural do Pará
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to host Nov. 4 webcast for financial results update - Stock Titan
How Corvus Pharmaceuticals Inc. stock reacts to Fed rate cuts - fcp.pa.gov.br
Will Corvus Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & AI Based Trade Execution Alerts - fcp.pa.gov.br
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Analyst Downgrade & Safe Swing Trade Setup Alerts - newser.com
Aug Summary: Why Corvus Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Selloffs & Real-Time Stock Price Movement Reports - fcp.pa.gov.br
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):